EMA Application withdrawn: Raltegravir Viatris (raltegravir potassium) — Viatris Limited

View source ↗

Summary

The EMA has withdrawn the application for Raltegravir Viatris (raltegravir potassium) by Viatris Limited for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Raltegravir Viatris (raltegravir potassium)

Snippet

Status: Application withdrawn. Therapeutic area: HIV Infections. MAH: Viatris Limited